Posted in Regulatory Biogen Bounces Back With FDA Nod for High-Dose Spinal Muscular Atrophy Drug March 30, 2026 BioSpace The FDA rejected the high-dose regimen of Spinraza in September last year due to manufacturing concerns. RegulatoryRare DiseaseRead full story